Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2000 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

Actinium Pharmaceuticals (ATNM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Actinium Pharmaceuticals (ATNM) Stock Stands Out in a Strong Industry

Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%

Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.

Actinium Treats First Patient in AML Study on Actimab-A Combo

Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.

Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?

Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Actinium (ATNM) Upgraded to Strong Buy: Here's Why

Actinium (ATNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Actinium (ATNM) a New Buy Stock

News for Actinium Pharmaceuticals Stock (ATNM)